IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 335 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5,363 | -3.6% | 118,229 | -12.8% | 0.01% | +14.3% |
Q2 2023 | $5,562 | +16.1% | 135,556 | +1.2% | 0.01% | +16.7% |
Q1 2023 | $4,789 | -9.8% | 134,000 | -4.6% | 0.01% | -14.3% |
Q4 2022 | $5,307 | -99.9% | 140,500 | -1.7% | 0.01% | -22.2% |
Q3 2022 | $6,320,000 | +16.3% | 142,900 | -2.7% | 0.01% | +28.6% |
Q2 2022 | $5,435,000 | -0.0% | 146,825 | +0.0% | 0.01% | +16.7% |
Q1 2022 | $5,437,000 | +16.2% | 146,800 | -4.6% | 0.01% | +20.0% |
Q4 2021 | $4,680,000 | -42.1% | 153,800 | -36.2% | 0.01% | -44.4% |
Q3 2021 | $8,088,000 | -15.9% | 241,159 | 0.0% | 0.01% | -10.0% |
Q2 2021 | $9,620,000 | +7.9% | 241,159 | +21.7% | 0.01% | 0.0% |
Q1 2021 | $8,912,000 | -29.5% | 198,231 | -11.4% | 0.01% | -28.6% |
Q4 2020 | $12,650,000 | +12.7% | 223,731 | -5.4% | 0.01% | 0.0% |
Q3 2020 | $11,223,000 | -26.4% | 236,531 | -8.5% | 0.01% | -26.3% |
Q2 2020 | $15,249,000 | +18.8% | 258,631 | -4.8% | 0.02% | 0.0% |
Q1 2020 | $12,838,000 | -20.9% | 271,531 | +1.0% | 0.02% | 0.0% |
Q4 2019 | $16,236,000 | -0.2% | 268,758 | -1.1% | 0.02% | -9.5% |
Q3 2019 | $16,276,000 | -15.2% | 271,673 | -9.0% | 0.02% | -12.5% |
Q2 2019 | $19,186,000 | -20.6% | 298,516 | +0.3% | 0.02% | -22.6% |
Q1 2019 | $24,158,000 | +81.8% | 297,623 | +21.1% | 0.03% | +63.2% |
Q4 2018 | $13,291,000 | -12.6% | 245,848 | -16.6% | 0.02% | +5.6% |
Q3 2018 | $15,199,000 | +1.7% | 294,661 | -17.8% | 0.02% | -5.3% |
Q2 2018 | $14,939,000 | -10.3% | 358,500 | -5.2% | 0.02% | -9.5% |
Q1 2018 | $16,662,000 | -14.2% | 378,000 | -2.1% | 0.02% | -8.7% |
Q4 2017 | $19,416,000 | -1.2% | 386,000 | -0.4% | 0.02% | -8.0% |
Q3 2017 | $19,646,000 | +0.7% | 387,492 | +1.0% | 0.02% | -3.8% |
Q2 2017 | $19,508,000 | +25.6% | 383,492 | -0.7% | 0.03% | +23.8% |
Q1 2017 | $15,527,000 | -16.0% | 386,253 | +0.0% | 0.02% | -19.2% |
Q4 2016 | $18,474,000 | +30.5% | 386,252 | 0.0% | 0.03% | +30.0% |
Q3 2016 | $14,152,000 | +48.1% | 386,252 | -5.9% | 0.02% | +42.9% |
Q2 2016 | $9,557,000 | -42.6% | 410,352 | -0.3% | 0.01% | -44.0% |
Q1 2016 | $16,664,000 | -33.6% | 411,458 | +1.6% | 0.02% | -35.9% |
Q4 2015 | $25,085,000 | – | 405,051 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |